Pharmaceutical Industry

Prescription Drugs 

Revenues in the prescription drugs segment generated via brick-and-mortar and mail-order pharmacies grew by almost 6.5 percent per year between 2020 and 2024 (+7.5 percent in 2024), reaching almost EUR 70.3 billion in 2024 (ex-pharmacy prices). Prescription-only medicines accounted for 89 percent of drug sales revenue and for around half (around 800 million packaging units) of the sales volume of medicinal products in the pharmacy market. Germany´s ageing society and the high prevalence of chronic and long-term diseases will continue to drive demand for prescription drugs in the German market.  
 

Over-the-counter (OTC) Market   

Revenue in the German OTC market increased by seven percent in 2024, reaching almost EUR 13.8 billion. This corresponds to around 1.7 billion packaging units. More than EUR 8.8 billion of revenue was generated in the non-prescription drugs segment and around EUR 3.6 billion with health products that are not subject to pharmaceutical legislation, e.g. food supplements. With sales of almost EUR 1.4 billion in 2024, substance-based medical devices represented the smallest OTC segment.

Remedies for the respiratory system, analgesics and products for the digestive system account for the highest share of non-prescription drug sales via pharmacies. Although self-medication constitutes the lion’s share of OTC revenue, OTC products may also be prescribed and reimbursed by health insurers. 

Over-the-counter medicines may be dedicated to treating relatively minor ailments such as colds. Many consumers are also willing to spend money on products that support personal wellbeing, e.g. food supplements. Growing health awareness levels and a focus on prevention displayed by many consumers in Germany contribute to positive future prospects in the OTC segment.  

Biopharmaceuticals 
Because of their high therapeutic potential, biologics have taken up a considerable share of the pharmaceutical market in Germany. In 2024, revenue of biopharmaceutical manufacturers in Germany grew by 9.1 percent to EUR 21.4 billion – equivalent to more than one third of the total pharmaceutical market.  

With growth rates of 13 percent and 17 percent respectively, oncology and immunology remained the highest-revenue segments in 2024. Together with metabolic disorders, those three indication areas represent almost three quarters of total biopharmaceutical sales in Germany.  

Full R&D pipelines with many clinical studies focusing on oncology – followed by infectious diseases and immunology – contribute to a vibrant biotech ecosystem. The innovative strength of the German biotechnology sector and the diverse application possibilities of artificial intelligence will most probably further enhance industry growth. 
 

Germany is the perfect location for pharmaceutical R&D, production, and sales of medicines. We welcome international enterprises who seek to become a part of the country’s thriving life science ecosystem. 

• Attractive Pharma Production Location 

  Germany is one of the world’s top pharmaceutical production locations. In 2024, pharmaceutical production volume reached EUR 37.5 billion.

  Together with Ireland, Italy and Denmark, Germany belongs to the biggest pharmaceutical manufacturing locations within the European Union. In addition to local industry players like Bayer and Boehringer Ingelheim, many international pharmaceutical companies – including GlaxoSmithKline, Pfizer, Roche, Sanofi, and Takeda – operate production facilities in Germany.

  Germany is the fifth-largest producer of biopharmaceuticals worldwide and the second largest worldwide . Three important factors contributing to this excellent position are the high-performing industrial infrastructure, the longstanding strength of the local chemical industry, and a highly qualified workforce. 

• Excellent R&D Environment  

  Germany provides the perfect environment for the development and production of research-intensive, high-grade products. In 2024, the pharmaceutical industry in Germany invested over EUR 10.7 billion in R&D – far more than any other EU country. The German pharma sector shows the highest research intensity across all major German industries – about 11.1 percent of revenues were reinvested in internal R&D projects in 2024 and the total research intensity reached 16.9 percent.

  Based on the number of patent applications, the country is also leading in pharmaceutical innovation in Europe. In 2024, some 612 patents were registered with the European Patent Office by the pharmaceutical industry in Germany. With 541 clinical trials financed by research-based pharmaceutical companies in 2024, Germany ranks second in the EU and fifth worldwide after the USA, China , Spain and Australia respectively.  

  Over 30 biotechnology clusters bundle scientific expertise at a regional level and connect academic and industrial players in the field of drug development, thereby contributing substantially to the advancement of pharmaceutical innovation and creating an innovation ecosystem that enjoys global acclaim.
   

• Strong and Supportive Associations   
  
  International pharmaceutical companies can benefit from a well-established association landscape representing the interests of the pharmaceutical industry in Germany and positively shaping the business environment. Major organizations include: 
   

  • BPI – German Pharmaceutical Industry Association: www.bpi.de 

  • Pharma Deutschland: www.pharmadeutschland.de 

  • vfa – German Association of Research-Based Pharmaceutical Companies: www.vfa.de 

  • Pro Generika – German association of generics and biosimilar manufacturers: www.progenerika.de 

  • Recognizing the crucial importance of the pharmaceutical sector, the German government released a pharma strategy in 2023 to further enhance the attractiveness of Germany as a pharmaceutical R&D and production location.